Clinical Trials Logo
  1. Home
  2. Renal Cancer
  3. NCT01573156

Vascular Targeted Photodynamic Therapy T1a Renal Tumours — KCM201  

Renal Cancer Clinical Trial

Official title:
Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial

Clinical Trial Summary

Vascular Targeted Photodynamic therapy (VTP) with the Vascular Occluding Agent (VOA) WST11, may offer an alternative, providing tumour destruction via a minimally invasive approach. In this investigation, the investigators plan to use the WST11 VTP procedure to treat a predetermined small renal tumour targets. Patients will be given a general anaesthetic, to ensure immobility, and prevent discomfort during treatment sessions. Treated patients will then undergo surgical resection of their tumours, and the accuracy and reliability of tissue death with VTP will be assessed histologically. The aim of this proof of concept study is to demonstrate whether this modality has potential for a clinical role in the treatment of oncological kidney disease, either as an alternative to surgery, or where surgery is not feasible.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01573156
Study type Interventional
Source University of Oxford
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date May 2013
Completion date June 2015
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT00531284 - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1/Phase 2
Recruiting NCT05842044 - NSAID Use After Robotic Partial Nephrectomy Phase 2
Recruiting NCT05387863 - Decision Aid (DA) for Renal Patients N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Withdrawn NCT03390413 - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer N/A
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT03203473 - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Phase 2
Suspended NCT04115254 - Stereotactic Magnetic Resonance Guided Radiation Therapy N/A
Enrolling by invitation NCT02609269 - Decipher Genomics Resource for Intelligent Discovery
Terminated NCT01453595 - BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Phase 1/Phase 2
Completed NCT01444456 - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia N/A
Completed NCT02811250 - Stereotactic Radiotherapy for Renal Cancers N/A
Completed NCT00399152 - Perifosine + Sunitinib Malate for Patients With Advanced Cancers Phase 1
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Completed NCT00458536 - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Phase 1/Phase 2
Recruiting NCT03693014 - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Phase 2
Completed NCT00418496 - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Phase 1